BioChem Immunosystems aims to broaden UK portfolio:
This article was originally published in Clinica
Executive Summary
BioChem Immunosystems UK - previously Serono Diagnostics - aims to broaden its portfolio following acquisition by BioChem Immunosystems (Canada). The company currently sells monoclonal antibodies and makes hybridomas under licence agreements. Cell lines include AFP, CEA, insulin, TSH, FSH, hGC, LH, prolactin and phencyclidine.